Published in J Res Med Sci on October 18, 2016
Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections. N Engl J Med (2014) 28.65
Fruit bats as reservoirs of Ebola virus. Nature (2005) 11.05
Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ (1978) 9.23
Ebola haemorrhagic fever. Lancet (2011) 8.28
The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit. J Infect Dis (1999) 7.39
Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit. J Infect Dis (1999) 6.72
Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis (2007) 6.46
Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med (1999) 5.85
Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull World Health Organ (1978) 5.82
Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis (1999) 5.59
The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A (2000) 5.46
Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis (1999) 4.96
Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread. Bull World Health Organ (1983) 4.81
The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol (2003) 4.73
Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol (2003) 4.67
An outbreak of Ebola in Uganda. Trop Med Int Health (2002) 4.66
A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med (2014) 4.57
Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog (2009) 4.56
Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet (2010) 4.52
Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Dis (2009) 4.24
Experimental inoculation of plants and animals with Ebola virus. Emerg Infect Dis (1997) 4.03
Effective post-exposure treatment of Ebola infection. PLoS Pathog (2007) 3.69
Discovery of swine as a host for the Reston ebolavirus. Science (2009) 3.68
Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet (2003) 3.57
Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol (2006) 3.50
Cultural contexts of Ebola in northern Uganda. Emerg Infect Dis (2003) 3.35
Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis (2003) 3.33
Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis (2003) 3.15
[On the etiology of an unknown human infection originating from monkeys]. Dtsch Med Wochenschr (1967) 3.14
Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol (2004) 3.04
Discovery of an ebolavirus-like filovirus in europe. PLoS Pathog (2011) 2.99
Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature (2014) 2.98
Large serological survey showing cocirculation of Ebola and Marburg viruses in Gabonese bat populations, and a high seroprevalence of both viruses in Rousettus aegyptiacus. BMC Infect Dis (2009) 2.82
Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis (1999) 2.76
Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol (2003) 2.66
Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis (2007) 2.44
The natural history of Ebola virus in Africa. Microbes Infect (2005) 2.39
Spatial and temporal patterns of Zaire ebolavirus antibody prevalence in the possible reservoir bat species. J Infect Dis (2007) 2.37
Ebola virus outbreak among wild chimpanzees living in a rain forest of Côte d'Ivoire. J Infect Dis (1999) 2.34
Clinical manifestations and case management of Ebola haemorrhagic fever caused by a newly identified virus strain, Bundibugyo, Uganda, 2007-2008. PLoS One (2012) 2.33
An introduction to Ebola: the virus and the disease. J Infect Dis (1999) 2.33
Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis (2010) 2.24
The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses. FEBS Lett (1992) 2.24
Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch Pathol Lab Med (1996) 2.23
Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis (2006) 2.19
The ecology of Ebola virus. Trends Microbiol (2007) 2.08
Late ophthalmologic manifestations in survivors of the 1995 Ebola virus epidemic in Kikwit, Democratic Republic of the Congo. J Infect Dis (1999) 2.06
Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog (2006) 2.01
Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus. J Virol (2008) 1.96
Long-term survival of an urban fruit bat seropositive for Ebola and Lagos bat viruses. PLoS One (2010) 1.95
A review on therapeutic potential of Nigella sativa: A miracle herb. Asian Pac J Trop Biomed (2013) 1.84
Pathologic features of filovirus infections in humans. Curr Top Microbiol Immunol (1999) 1.83
Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res (2013) 1.79
Fatal human disease from vervet monkeys. Lancet (1967) 1.77
Proportion of deaths and clinical features in Bundibugyo Ebola virus infection, Uganda. Emerg Infect Dis (2010) 1.75
Outbreaks of Ebola virus disease in Africa: the beginnings of a tragic saga. J Venom Anim Toxins Incl Trop Dis (2014) 1.72
Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells. J Virol (1999) 1.68
Incubation period of ebola hemorrhagic virus subtype zaire. Osong Public Health Res Perspect (2011) 1.67
An analysis of features of pathogenesis in two animal models of Ebola virus infection. J Infect Dis (1999) 1.67
Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis (1989) 1.65
Ebola virus antibodies in fruit bats, Ghana, West Africa. Emerg Infect Dis (2012) 1.62
Isolation and phylogenetic characterization of Ebola viruses causing different outbreaks in Gabon. Emerg Infect Dis (1997) 1.56
Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques. Viral Immunol (2004) 1.55
Ebola virus antibodies in fruit bats, bangladesh. Emerg Infect Dis (2013) 1.54
Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection. J Pathol (1985) 1.52
Disseminated intravascular coagulation. Crit Care Med (2007) 1.51
Trigger events: enviroclimatic coupling of Ebola hemorrhagic fever outbreaks. Am J Trop Med Hyg (2004) 1.45
Viral hemorrhagic fever hazards for travelers in Africa. Clin Infect Dis (2001) 1.45
Ebola outbreak in Conakry, Guinea: epidemiological, clinical, and outcome features. Med Mal Infect (2014) 1.43
Medical anthropology and Ebola in Congo: cultural models and humanistic care. Bull Soc Pathol Exot (2005) 1.30
Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses. FASEB J (2006) 1.28
Clinical management of filovirus-infected patients. Viruses (2012) 1.26
Apoptosis in fatal Ebola infection. Does the virus toll the bell for immune system? Apoptosis (2000) 1.25
Ebolavirus and Marburgvirus: insight the Filoviridae family. Mol Aspects Med (2007) 1.23
Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells. HPB (Oxford) (2009) 1.22
Therapy and prophylaxis of Ebola virus infections. Curr Opin Investig Drugs (2005) 1.16
The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. PLoS Pathog (2012) 1.16
Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch Virol (2013) 1.10
Marburg hemorrhagic fever: report of a case studied by immunohistochemistry and electron microscopy. Ultrastruct Pathol (1998) 1.09
Suppressive effect of Ebola virus on T cell proliferation in vitro is provided by a 125-kDa GP viral protein. Immunol Lett (1999) 1.04
Nigella sativa modulates splenocyte proliferation, Th1/Th2 cytokine profile, macrophage function and NK anti-tumor activity. J Ethnopharmacol (2010) 1.02
Nigella sativa relieves the deleterious effects of ischemia reperfusion injury on liver. World J Gastroenterol (2008) 1.00
Experimental study on the possibility of treatment of some hemorrhagic fevers. J Biotechnol (2000) 0.97
Fighting Ebola with ZMapp: spotlight on plant-made antibody. Sci China Life Sci (2014) 0.97
Laboratory diagnosis of Ebola virus disease. Intensive Care Med (2015) 0.96
Effect of thymoquinone on cyclooxygenase expression and prostaglandin production in a mouse model of allergic airway inflammation. Immunol Lett (2006) 0.96
Filoviruses: recent advances and future challenges. J Infect Dis (2007) 0.89
Anti-inflammatory effect of seeds and callus of Nigella sativa L. extracts on mix glial cells with regard to their thymoquinone content. AAPS PharmSciTech (2012) 0.86
Identification of Ebola virus microRNAs and their putative pathological function. Sci China Life Sci (2014) 0.85
Seasonal variation in antibodies against Ebola virus in Kenyan fever patients. Lancet (1986) 0.83
Progress of vaccine and drug development for Ebola preparedness. Clin Exp Vaccine Res (2015) 0.82
Nigella sativa: A Potential Antiosteoporotic Agent. Evid Based Complement Alternat Med (2012) 0.82
Viral haemorrhagic fever. Clin Med (2015) 0.79
[The epidemic of hemorrhagic fever in Zaire (August-November 1976) and its implications]. Verh K Acad Geneeskd Belg (1983) 0.76
[Illness due the Ebola virus: epidemiology and clinical manifestations within the context of an international public health emergency]. Rev Neurol (2015) 0.76